PERCEPTIVE ADVISORS LLC - 28 May 2021 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Director
Signature
/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Issuer symbol
ATHA
Transactions as of
28 May 2021
Net transactions value
$0
Form type
4
Filing time
01 Jun 2021, 19:58:59 UTC
Previous filing
11 Jun 2021
Next filing
03 Jun 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +13,871 $0.000000 13,871 28 May 2021 Common Stock 13,871 $19.94 See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest on the earlier of (i) May 28, 2022, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 28, 2021.
F2 Consists of options to purchase shares of the Issuer's common stock awarded to Joseph Edelman in connection with his role as a member of the Issuer's Board of Directors. Mr. Edelman is the managing member of Perceptive Advisors LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset.